Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What an amazing ignition switch flip as usual subs buddy choo-choo;)
Limited shares available As of June 6, 2022, there were 7,821,515 shares of the registrant's common stock, $0.00001 par value per share, outstanding.
just blew past 1.50 volume nearing 2 milly....weee
this is past 1.35 now just crossed 1 milly in volume in almost the first half hour....up over .40 cents......somethings up
In the last twelve months, the biggest single purchase by an insider was when Director David Neal bought US$150k worth of shares at a price of US$4.35 per share. That means that an insider was happy to buy shares at above the current price of US$0.84. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.
up .10 pre market. volume at a half million in the first half hour......what's brewing under the surface here?
They need to get the shares to bid 1.00 or higher for 7 consecutive days to be NASDAQ compliant.
Need some sales numbers - revenue numbers. Earnings going to be dismal I'm betting. Yet that's unfortunate, because I think their technology is very helpful.
Company has had ample time to give us some sort of PR. Silence this long is NOT golden IMO. I'm done. Best of luck to those who stay patient.
This company doesn't seem to have anything to sell that anybody wants. New quarterly report says they have dropped about one quarter of their revenue because people stopped ordering the scan and they had a net loss of users! They are making less than $700 a week in revenue, big debts, evaporating user base, and burning cash with nothing to show for it. Reminds me of that onion video about the money pit. Everybody who invested has probably done their money. That's what happens when people invest based on hype.
According to Yahoo statistics on ACON, there is ONLY 7.82 million shares outstanding on their stock.
One decent PR can send the share price into the stratosphere with their low share count.
Uhhhh ... look WHO owns over a million shares of ACON!:
NuVasive is a medical devices company based in San Diego, California. The company primarily develops medical devices and procedures for minimally invasive spine surgery. NuVasive's products include software systems for surgical planning and monitoring, access instruments, and implantable hardware.
How many international markets does NuVasive conduct business in?
With more than $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals, and patients.
Now we know why the share price was taken so low. Accumulation! (Of course).
Hopefully we are steadily climbing from here.
What gains my attention with ACON is the possibility that in time, insurance companies may MANDATE MRS testing BEFORE even approving payment for disc replacement.
Furthermore, caught in time through MRI - MRS testing ... medical professionals and insurance companies are placing more and more emphasis on "spinal disc support therapy" and less on spinal disc replacement/s.
"Spinal disc support therapy" may be best understood when it is likened to planting a small tomato plant in early summer where it can be very windy. The little vulnerable tomato plant can get weakened or blown completely over by wind, so the wise gardener gives it a "support stake" until it becomes big enough to stand strong winds. (Rods and screws and NEWLY IMPROVED support procedures for vertebrae to take pressure off the disc/s).
A spine that is radiating pain from one or more discs ... if caught in time before there is too much disc deterioration ... (detected through early MRI - MRS testing) ... can be given "support stakes" through much less invasive surgical procedures to STOP one or more discs from further deterioration (hence one day needing disc replacement, which THEN places the patient in a much HIGHER risk category of dealing with MORE UNNECESSARY PAIN in years to follow in that area).
Sure could use a "peep" out of the company.
ACON moving up nicely. We should close @ 2.40+
One decent PR can send this back up to $4 and OVER in a New York second.
If you look at the very top of the Aclarion website, it reads: Nocimed is now Aclarion. https://aclarion.com/
The article below gives greater insight for those wanting to learn MORE about Aclarion's spinal pain diagnostic technology.
By Elizabeth Hofheinz, M.P.H., M.Ed., October 4, 2019
If one of the most defining human traits is a need for certainty, you can double that for surgeons. Hence the frustration for spine surgeons when it comes to treating low back pain, arguably one of the most elusive orthopedic conditions to diagnose and treat.
But Nocimed, Inc. is making a dent in that problem. This San Mateo, California-based spine business is the only company in the world that is exploring the role of chemical biomarkers in helping to diagnose lumbar disc pain. Based on MR Spectroscopy, Nocimed puts more and better decision-making power in the hands of surgeons.
CEO Brett Lanuti notes: “Drs. Jeff Lotz and David Bradford, along with Jim Peacock, founded Nocimed in 2008 essentially because of the unpredictability of surgical outcomes for low back pain patients. They could see that a better option was necessary as a traditional MRI was unable to provide sufficient information.”
Chemical cocktail…
Thus, the founders went on a scientific quest for quantifiable information that would shed light on the chemical cocktail that might be responsible for low back pain.
Brett Lanuti: “Conventional thinking says that a dark disc in MRI indicates pain while a light disc is void of pain because it is hydrated. The early research at the University of California at San Francisco (UCSF) looked at tissue samples under a high field MRI and found that in a scoliotic disc there were high levels of glycogens and low acids. Then they examined tissue samples from patients undergoing lumbar surgery for back pain and saw low proteoglycan and high acids.”
Going beyond the noise…
Licensing this technology that was invented at the UCSF, Nocimed knew it was onto something. Lanuti stated, “We knew that this had never been done for the spine before and that spectroscopy can be difficult to interpret unless you can increase the signal to noise ratio. The solution took several years to develop, but ultimately is now one of many patents Nocimed holds as part of our software portfolio.”
And their work paid off. “Using spectroscopy, we were able to find the ‘fingerprint’ of a disc much more easily as we were able to capture the signal spikes of individual biomarkers We are taking raw biomarkers and post processing them with an algorithm to create a report which provides a valuable adjunctive piece of information in order to assess acids and collagen in the disc.”
So what do patients undergo? It starts with a conventional lumbar MRI, with spectroscopy added within the same session. The resulting data is then uploaded to a cloud-based system for analysis that is processed into a readable report, i.e., a “Nocigram.”
A resounding ‘thank you’ from surgeons…
Matt Gornet, M.D., a spine surgeon at the Orthopedic Center of St. Louis, states, “Nociscan has changed my practice. For years we’ve had to use a variety of limited tools in diagnosing discogenic low back pain. Now, with Nociscan, I have a tool that scientifically enables me to identify and then treat the source of patients’ low back pain.”
Roger Sung, M.D., with Colorado Springs Orthopedics Group, noted, “I find that Nociscan can be most beneficial in the setting of a patient with very clear pathology at one level (spondy and stenosis) with radicular symptoms. These patients often have significant low back pain as well. I know that this level needs to be fused. Nociscan can help to identify whether an adjacent segment with mild age-related wear is a significant component of this patient’s low back pain. If it is, including it in the fusion can help significantly with low back pain. If it’s negative, leaving it alone is better for the patient and cheaper for the insurance company in terms of time of surgery, complications, implant costs, etc. If this adjacent disc level is painful and included in the surgery and the patient has a better result, the insurance costs are less as there is less long-term treatment, less chance of a second surgery soon, etc. In either scenario, the information and the correct treatment based on the Nociscan information combined with the conventional diagnostic information can save significant costs.”
The technology, which functions on the Siemens platform, is in high demand, says Lanuti. “Imaging centers are quickly adopting this technology as it clearly addresses an unmet need.”
Brett Lanuti: “We now know that it is possible to monitor interdiscal health over a period of time as long as there has been no fusion. So patient X had painful discs, underwent conservative therapy, and six months later showed a reduction in acids within the disc. Clinicians are telling us that they are relieved to finally see an adjunctive tool in this market that can better address the gap in diagnosing chronic back pain.”
An orthopedic business for the greater good…
“The number two consumers of opioids are chronic back pain patients,” says Lanuti. “The Nocimed technology can be used for the greater good as it can help patients get the right treatment at the right time, thus obviating or lessening the need for opioids.”
“Using a large payor database, we were able to demonstrate well over $200 million in savings over four years through the reduction of adjacent segment surgery. It is a fact that 9% of all patients who undergo lumbar spine surgery go on to need an adjacent level surgery at some point. Information from the Nocimed report can help reduce that number, and in doing so, reduce suffering, and unnecessary surgery.”
Douglas Beall, M.D. of the Center of Radiology of Oklahoma states, “Nociscan is filling a major and long-standing gap in the diagnostics of low back pain. It’s not an exaggeration to believe that years from now, Nociscan will be as commonly used as the flu vaccine in an effort to address this significant gap.”
But in the meantime, Nocimed is proceeding in a methodic manner and establishing the validity of its product. Brett Lanuti notes, “We expect to have 10 imaging centers utilizing the Nocimed technology by the end of this year. In addition, we have just launched a Post Market Study where we will enroll 240 patients at 8-10 of the leading Spine Centers in the US to support our previously published data which had been published in the European Spine Journal earlier this year. We are expecting to see similar results validating the NOCISCAN-LS as an adjunctive diagnosis tool helping in the improvement of surgical and non-surgical patient outcomes.”
Yep, wild alright ... yet still a sleeper. Wish I had a lot more cash to get these cheap shares while they are still cheap. My gut feeling is that we have a HUGE money maker here.
All have a great day!
Once institutions get wind of Aclarion's technology ... ohhhhhhhhhhhh MMMMMMMMMMMMMMMYYYYYYYYYYYY!
Public float is so low. 10% owners and insiders will hold their shares
This is NOT a stock to sneeze at!: https://aclarion.com/
Man -- this technology could easily be worth $100+ a share depending on how effective it is!
Cheap shares under $2.00 are hard to get. Wanting to add shares to my stash but MM's not filling my order/s. Grrrrrrrrrrrrrrrrrrrrr ...
Shorts come first I reckon.
Insiders and beneficial owners are in at 4.35 IPO price
Letting the shorts cover before letting it run on its own.
Yep - this will be a hold for me as well. Far too much potential in the field of medicine they are in for this to remain this low in price for very long.
I am not selling a single share. They did not do an IPO to stay silent forever.
I would think anything under $2.00 is an absolutely STEAL.
I have been loading up here for days. Good luck!
Yep little bit more volume and this might get a nice squeeze.
1.92's for me. > LET'S GO ACON!
Yep snagged some 1.93s
ACON up 10% IPO on April 22; Float is 2.64M Shares
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), and a proprietary biomarker to optimize clinical treatments. Aclarion's technology addresses the $134.5B U.S. low back and neck pain market. The Company is currently utilizing Artificial Intelligence ("AI") to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. The Company is also researching the application of AI and machine learning platforms to analyze both the raw spectroscopy data and the post-processed signal to evaluate whether AI platforms can more efficiently and more effectively associate MRS data with clinical outcomes.
Public float reduced from 3.24 million last week to 2.64M now
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
167
|
Created
|
04/28/22
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |